In early September, Arizona's attorney general filed a consumer fraud lawsuit against L'Oreal USA over its hair relaxer products. The filing adds a state-level legal front to what has already become a sprawling mass tort: more than 11,000 individual cases are consolidated in federal court, all alleging that the same chemical formulas marketed to Black women caused uterine, ovarian, and endometrial cancers.
The headline soundbite is about cancer. The investment question is about scale.
L'Oreal SA, the Paris-listed cosmetics giant, is worth roughly €200 billion and generated €44 billion in sales last year. Its Consumer Products division, which sells Dark & Lovely, ORS, and Motions — the brands at the centre of the litigation — brought in €16 billion. Even if a material settlement eventually emerges, the hair relaxer franchise is a narrow slice of a broad, diversified operation. The legal risk is real, but it is unlikely to reshape the business economics of a company that outperforms the beauty market across every continent and category.
Quick Backtesting Tool
To understand why, the litigation needs unpacking. And the numbers need comparing.
How the lawsuit grew, and where it is now
The legal storm began in October 2022, when the National Institutes of Health published a study of nearly 34,000 women. It found that those who used chemical relaxers four or more times a year had roughly double the risk of developing uterine cancer: a 4.05 per cent lifetime probability by age 70, compared with 1.64 per cent for never-users. The study showed association, not causation, and scientists were careful to note the absence of a specific chemical culprit. That caution has not deterred plaintiffs.
Within months, the cases multiplied. By the end of 2024, the multi-district litigation, known as MDL 3060 and based in the Northern District of Illinois, had grown from around 60 cases to nearly 10,000. As of April this year, the docket held 11,371 pending claims. The named defendants include L'Oreal, Revlon, SoftSheen-Carson, and a host of smaller manufacturers. Arizona's filing is separate from the MDL — it is a state consumer fraud action brought by Arizona Attorney General Kris Mayes, who alleges the company misled purchasers about cancer risks.
The litigation has not yet reached a courtroom. A federal judge selected 10 bellwether cases — the test trials that will set the tone — in April 2026. Discovery deadlines have been set. Daubert challenges to the scientific evidence are in the pipeline. The first bellwether trials are not expected until sometime in 2027. No verdicts have been rendered. No settlements have been announced.
The practical effect is a long period of legal uncertainty during which L'Oreal is paying lawyers, producing documents, and managing reputational risk — but has not been found liable or required to pay damages.
What the exposure looks like against the company's finances
This is where scale matters most. The hair relaxer brands are part of L'Oreal's Consumer Products division, which also sells L'Oreal Paris cosmetics, Garnier skincare, Maybelline makeup, and Nyx professional products globally. That division generated €16.09 billion in revenue in 2025 and operates at a 21.4 per cent margin, producing €3.44 billion in operating profit.
The U.S. Black hair care market as a whole was worth roughly $1.4 billion in 2025. Hair relaxers are a segment within that segment. Even if every relaxer brand were removed from shelves, the direct revenue loss would be a rounding error against €44 billion in annual group sales. The more plausible scenario is not product withdrawal but litigation costs and eventual settlement payments.
Mass tort settlements in comparable cases have ranged widely. The talc litigation against Johnson & Johnson resulted in a subsidiary bankruptcy — but J&J's consumer-spin Kenvue absorbed the risk through a structural separation, a manoeuvre available to a company with a different product mix. The Roundup herbicide settlement cost Monsanto's owners $10.9 billion, but Monsanto was a single-product business. L'Oreal's four divisions — Consumer Products, Luxe, Professional Products, and Dermatological Beauty — all grew organically last year. The Dermatological Beauty division alone, with its CeraVe and La Roche-Posay brands, generated €7.2 billion in revenue and a 26.1 per cent operating margin.
That diversification is the structural reason the litigation is unlikely to be existential. A settlement of even several billion euros would be absorbed by a company that produces €7.2 billion in net cash flow annually.
What an investor should actually worry about
The risk here is not financial collapse. It is three more mundane problems.
First, there is discovery exposure. Federal judges have already referred disputes over L'Oreal's internal documents to special masters. The Philadelphia court has ordered depositions of senior company officials. If internal communications surface showing earlier awareness of risk, they could inflame public sentiment, trigger additional state-level actions, and complicate settlement negotiations. That is reputational and political risk, not balance-sheet risk.
Second, there is the question of whether the litigation accelerates a consumer shift that was already underway. Many women have been moving away from chemical relaxers towards protective styles and natural hair care, driven by cultural trends as much as health concerns. The lawsuits may speed that transition along. But again, the revenue at stake is narrow, and L'Oreal has the R&D and brand portfolio to reformulate or pivot within the same customer base.
Third, there is the timing of the bill. Settlement watchers have pointed to late 2026 as a possible window for global negotiations, with payouts beginning in 2027. That timeline could change dramatically once the first bellwether trials produce verdicts. A series of plaintiff wins would increase settlement pressure. A series of dismissals or defendant victories would embolden L'Oreal to fight. The outcome of those trials is the single most important variable in the whole case.
What the stock market is telling you
The market appears to have done little to price in the litigation. L'Oreal's shares were trading around €381 on the Paris exchange earlier this week, close to their range for most of 2026. The stock trades at over 30 times earnings, a premium that reflects expectations of sustained margin expansion and growth, particularly in emerging markets and e-commerce. That multiple is not cheap. But the hair relaxer lawsuits are not the reason for it.
If anything, the litigation is a footnote in L'Oreal's investor relations materials. The company has dismissed the claims as having "no legal merit" and has not disclosed a specific litigation reserve tied to the hair relaxer cases in its public filings. That absence of a meaningful provision suggests management either expects the exposure to be manageable or judges it too uncertain to quantify — both interpretations point to a risk that is material enough to watch but not large enough to change the investment case.
The actual trade-off
This is not a story about a company about to fall apart. It is a story about a diversified global brand facing a long, expensive, and genuinely uncertain legal battle over a small segment of its business. The lawsuits are real, the NIH study is serious, and the social dimension — predominantly Black women bearing the health burden — is important. None of that changes the arithmetic: L'Oreal's size, diversification, and cash generation make it one of the better-positioned companies to absorb a mass-tort outcome.
The valuation is the more pressing concern. A stock trading at 30-plus times earnings leaves little margin for error on any front — litigation or otherwise. The hair relaxer lawsuits are not what makes L'Oreal an unattractive buy today. They are just one more reason not to assume that scale insulates every downside.
